Cargando…

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

Capecitabine and docetaxel are both active against a variety of solid tumours, while their toxicity profiles only partly overlap. This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pronk, L C, Vasey, P, Sparreboom, A, Reigner, B, Planting, A S Th, Gordon, R J, Osterwalder, B, Verweij, J, Twelves, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374547/ https://www.ncbi.nlm.nih.gov/pubmed/10883663 http://dx.doi.org/10.1054/bjoc.2000.1160

Ejemplares similares

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
por: Pronk, L. C., et al.
Publicado: (1998)

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
por: Thomson, A H, et al.
Publicado: (1999)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
por: Attard, G, et al.
Publicado: (2007)

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
por: Twelves, C J, et al.
Publicado: (1999)

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study
por: Fokkema, E, et al.
Publicado: (2000)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel
por: Veitia, R, et al.
Publicado: (2000)

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review
por: Engels, F K, et al.
Publicado: (2005)

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial
por: Ernst, T, et al.
Publicado: (2007)

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
por: Vasey, P A, et al.
Publicado: (2002)

Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival
por: Ragnarsson, G, et al.
Publicado: (1999)

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
por: Planting, A. S., et al.
Publicado: (1993)

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
por: Eskens, F A L M, et al.
Publicado: (2014)

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
por: Schellens, J. H., et al.
Publicado: (1996)

Capecitabine in the treatment of metastatic renal cell carcinoma
por: Oevermann, K, et al.
Publicado: (2000)

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts
por: Konerding, M A, et al.
Publicado: (1999)

Sigma-2 receptors as a biomarker of proliferation in solid tumours
por: Wheeler, K T, et al.
Publicado: (2000)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours
por: Scotton, C, et al.
Publicado: (2001)

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer
por: Korkeila, E. A., et al.
Publicado: (2017)

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study
por: Li, Jinyu, et al.
Publicado: (2015)

Comparative genomic hybridization and chromosomal instability in solid tumours
por: Rooney, P H, et al.
Publicado: (1999)

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy
por: de Wit, R, et al.
Publicado: (2001)

Phase 1 study on docetaxel and ifosfamide in patients with advanced solid tumours
Publicado: (1998)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer
por: Dassen, Anneriet E, et al.
Publicado: (2016)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Water-soluble aluminium phthalocyanine–polymer conjugates for PDT: photodynamic activities and pharmacokinetics in tumour-bearing mice
por: Brasseur, N, et al.
Publicado: (1999)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
por: Deenen, Maarten J., et al.
Publicado: (2011)

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
por: Vasey, P A, et al.
Publicado: (2003)

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
por: Ray-Coquard, I, et al.
Publicado: (2001)

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts
por: Thuss-Patience, P C, et al.
Publicado: (2011)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor
por: Sparreboom, A, et al.
Publicado: (2004)

Complete Remission of Advanced Gastric Cancer in Response to Chemotherapy With Docetaxel, Cisplatin and Capecitabine (dcx)
por: Marroqui, Asuncion Juarez, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tppmtbmsdb7t8l9dh5ftofl395